Proton Pump Inhibitors and Survival Outcomes in Patients With Metastatic Renal Cell Carcinoma

We showed that PPI use does not appear to negatively affect the efficacy and safety of select VEGF-TKIs in patients with mRCC. Documentation of concomitant medications and patient education on potential drug interactions are critical for optimizing the use of oral cancer-targeting therapy.